市場調查報告書

肌肉骨骼痛 - 市場洞察,流行病學,市場預測 2028年

Musculoskeletal Pain - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 787160
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
肌肉骨骼痛 - 市場洞察,流行病學,市場預測 2028年 Musculoskeletal Pain - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國,英國,德國,法國,西班牙,義大利,日本)的肌肉骨骼痛2018年患者數推算為2億5,404萬5,592人,市場規模推算為37億9,260萬美元。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的肌肉骨骼痛市場調查,總括性彙整市場概要,概要和現行的治療方法,新藥的簡介,市場趨勢,流行病學的預測,市場規模,近視人口的變化與預測,流行病學的預測,市場規模,近視人口的變化與預測等資訊。

目錄

第1章 主要洞察

第2章 肌肉骨骼痛概要

  • 2016年的分佈情形
  • 2027年的分佈情形

第3章 肌肉骨骼痛:疾病背景和概要

  • 簡介
  • 疼痛一般方面
  • 肌肉骨骼痛的類型
  • 肌肉骨骼痛的症狀
  • 肌肉骨骼痛的原因
  • 肌肉骨骼痛的基本
  • 肌肉骨骼痛的中樞機構
  • 肌肉骨骼痛的病理學
  • 肌肉骨骼痛的診斷
  • 肌肉骨骼痛的生物標記
  • 疼痛的檢測器具

第4章 流行病學和患者人口

  • 主要調查結果

第5章 主要7個國家肌肉骨骼痛的整體患者數

第6章 美國

  • 假設和理論的根據
  • 肌肉骨骼痛的整體患者數
  • 肌肉骨骼痛的患病數:性別
  • 肌肉骨骼痛的患病數:各類型
  • 肌肉骨骼痛的患病數:部位別

第7章 歐洲5個國家

  • 德國
    • 假設和理論的根據
    • 肌肉骨骼痛的整體患者數
    • 肌肉骨骼痛的患病數:性別
    • 肌肉骨骼痛的患病數:各類型
    • 肌肉骨骼痛的患病數:部位別
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 救命診療部的肌肉骨骼痛的治療

  • 老年人的慢性肌肉骨骼痛
  • 對慢性肌肉骨骼痛的治療流程

第9章 未滿足需求

第10章 新藥

  • 交叉競爭
  • NKTR-181:Nektar Therapeutics
    • 醫藥品概要
    • 其他開發活動
    • 臨床開發
    • 安全性和有效資畫兒
    • 產品簡介
  • Ampion:Ampio Pharmaceuticals
  • Tanezumab:Eli Lilly/Pfizer
  • Fasinumab:Regeneron Pharmaceuticals
  • CNTX-4975:Centrexion Therapeutics
  • MPC-06-ID (Rexlemestrocel-L):Mesoblast
  • Tizaspray:MDM S.p.A
  • CAM2038:Braeburn Pharmaceuticals
  • Egalet-002:Egalet Corporation

第11章 肌肉骨骼痛:主要7個國家的市場分析

  • 主要調查結果
  • 主要7個國家肌肉骨骼痛市場規模

第12章 美國:市場預測

  • 美國的市場規模
    • 肌肉骨骼痛的整體市場規模
    • 肌肉骨骼痛的市場規模:各治療藥物

第13章 歐盟5國:市場預測

  • 德國的市場規模
    • 肌肉骨骼痛的整體市場規模
    • 肌肉骨骼痛的市場規模:各治療藥物
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模

第14章 日本:市場預測

  • 日本的市場規模
    • 肌肉骨骼痛的整體市場規模
    • 肌肉骨骼痛的市場規模:各治療藥物

第15章 市場成長要素

第16章 市場障礙

第17章 附錄

  • 報告作成方法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0437

DelveInsight's "Musculoskeletal Pain - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Musculoskeletal Pain, historical and forecasted epidemiology as well as the Musculoskeletal Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Musculoskeletal Pain market report provides current treatment practices, emerging drugs, Musculoskeletal Pain market share of the individual therapies, current and forecasted Musculoskeletal Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Musculoskeletal Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Musculoskeletal Pain Disease Understanding and Treatment Algorithm

The DelveInsight Musculoskeletal Pain market report gives a thorough understanding of the Musculoskeletal Pain by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Musculoskeletal Pain.

Treatment

It covers the details of conventional and current medical therapies available in the Musculoskeletal Pain market for the treatment of the condition. It also provides Musculoskeletal Pain treatment algorithms and guidelines in the United States, Europe, and Japan.

Musculoskeletal Pain Epidemiology

The Musculoskeletal Pain epidemiology division provide insights about historical and current Musculoskeletal Pain patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Musculoskeletal Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Musculoskeletal Pain Epidemiology

The epidemiology segment also provides the Musculoskeletal Pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Musculoskeletal Pain Drug Chapters

Drug chapter segment of the Musculoskeletal Pain report encloses the detailed analysis of Musculoskeletal Pain marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Musculoskeletal Pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Musculoskeletal Pain treatment.

Musculoskeletal Pain Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Musculoskeletal Pain treatment.

Musculoskeletal Pain Market Outlook

The Musculoskeletal Pain market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Musculoskeletal Pain market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Musculoskeletal Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Musculoskeletal Pain market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Musculoskeletal Pain market in 7MM.

The United States Market Outlook

This section provides the total Musculoskeletal Pain market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Musculoskeletal Pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Musculoskeletal Pain market size and market size by therapies in Japan is also mentioned.

Musculoskeletal Pain Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Musculoskeletal Pain market or expected to get launched in the market during the study period 2017-2030. The analysis covers Musculoskeletal Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Musculoskeletal Pain Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Musculoskeletal Pain key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Musculoskeletal Pain emerging therapies.

Reimbursement Scenario in Musculoskeletal Pain

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Musculoskeletal Pain domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Musculoskeletal Pain market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Musculoskeletal Pain Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Musculoskeletal Pain, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Musculoskeletal Pain epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Musculoskeletal Pain are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Musculoskeletal Pain market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Musculoskeletal Pain market

Report Highlights

  • In the coming years, Musculoskeletal Pain market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Musculoskeletal Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Musculoskeletal Pain. Launch of emerging therapies will significantly impact the Musculoskeletal Pain market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Musculoskeletal Pain
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Musculoskeletal Pain Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Musculoskeletal Pain Pipeline Analysis
  • Musculoskeletal Pain Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Musculoskeletal Pain Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Musculoskeletal Pain Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Musculoskeletal Pain Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Musculoskeletal Pain market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Musculoskeletal Pain total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Musculoskeletal Pain market size during the forecast period (2017-2030)?
  • At what CAGR, the Musculoskeletal Pain market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Musculoskeletal Pain market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Musculoskeletal Pain market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Musculoskeletal Pain?
  • What is the historical Musculoskeletal Pain patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Musculoskeletal Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Musculoskeletal Pain?
  • Out of all 7MM countries, which country would have the highest prevalent population of Musculoskeletal Pain during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Musculoskeletal Pain treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Musculoskeletal Pain in the USA, Europe, and Japan?
  • What are the Musculoskeletal Pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Musculoskeletal Pain?
  • How many therapies are developed by each company for Musculoskeletal Pain treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Musculoskeletal Pain treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Musculoskeletal Pain therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Musculoskeletal Pain and their status?
  • What are the key designations that have been granted for the emerging therapies for Musculoskeletal Pain?
  • What are the global historical and forecasted market of Musculoskeletal Pain?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Musculoskeletal Pain market
  • To understand the future market competition in the Musculoskeletal Pain market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Musculoskeletal Pain in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Musculoskeletal Pain market
  • To understand the future market competition in the Musculoskeletal Pain market

Table of Contents

1. Key Insights

2. Executive Summary of Musculoskeletal Pain

3. Competitive Intelligence Analysis for Musculoskeletal Pain

4. Musculoskeletal Pain: Market Overview at a Glance

  • 4.1. Musculoskeletal Pain Total Market Share (%) Distribution in 2017
  • 4.2. Musculoskeletal Pain Total Market Share (%) Distribution in 2030

5. Musculoskeletal Pain: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Musculoskeletal Pain Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Musculoskeletal Pain Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Musculoskeletal Pain Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Musculoskeletal Pain Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Musculoskeletal Pain Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Musculoskeletal Pain Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Musculoskeletal Pain Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Musculoskeletal Pain Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Musculoskeletal Pain Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Musculoskeletal Pain Treatment and Management
  • 8.2. Musculoskeletal Pain Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Musculoskeletal Pain Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Musculoskeletal Pain: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Musculoskeletal Pain Market Size in 7MM
  • 13.3. Musculoskeletal Pain Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Musculoskeletal Pain Total Market Size in the United States
    • 15.1.2. Musculoskeletal Pain Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Musculoskeletal Pain Total Market Size in Germany
    • 15.3.2. Musculoskeletal Pain Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Musculoskeletal Pain Total Market Size in France
    • 15.4.2. Musculoskeletal Pain Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Musculoskeletal Pain Total Market Size in Italy
    • 15.5.2. Musculoskeletal Pain Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Musculoskeletal Pain Total Market Size in Spain
    • 15.6.2. Musculoskeletal Pain Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Musculoskeletal Pain Total Market Size in the United Kingdom
    • 15.7.2. Musculoskeletal Pain Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Musculoskeletal Pain Total Market Size in Japan
    • 15.8.3. Musculoskeletal Pain Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Musculoskeletal Pain

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Musculoskeletal Pain Epidemiology (2017-2030)
  • Table 2 : 7MM Musculoskeletal Pain Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Musculoskeletal Pain Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Musculoskeletal Pain Epidemiology in Germany (2017-2030)
  • Table 6 : Musculoskeletal Pain Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Musculoskeletal Pain Epidemiology in France (2017-2030)
  • Table 8 : Musculoskeletal Pain Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Musculoskeletal Pain Epidemiology in Italy (2017-2030)
  • Table 10 : Musculoskeletal Pain Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Musculoskeletal Pain Epidemiology in Spain (2017-2030)
  • Table 12 : Musculoskeletal Pain Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Musculoskeletal Pain Epidemiology in the UK (2017-2030)
  • Table 14 : Musculoskeletal Pain Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Musculoskeletal Pain Epidemiology in Japan (2017-2030)
  • Table 16 : Musculoskeletal Pain Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Musculoskeletal Pain Epidemiology (2017-2030)
  • Figure 2 : 7MM Musculoskeletal Pain Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Musculoskeletal Pain Epidemiology in the United States (2017-2030)
  • Figure 4 : Musculoskeletal Pain Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Musculoskeletal Pain Epidemiology in Germany (2017-2030)
  • Figure 6 : Musculoskeletal Pain Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Musculoskeletal Pain Epidemiology in France (2017-2030)
  • Figure 8 : Musculoskeletal Pain Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Musculoskeletal Pain Epidemiology in Italy (2017-2030)
  • Figure 10 : Musculoskeletal Pain Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Musculoskeletal Pain Epidemiology in Spain (2017-2030)
  • Figure 12 : Musculoskeletal Pain Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Musculoskeletal Pain Epidemiology in the UK (2017-2030)
  • Figure 14 : Musculoskeletal Pain Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Musculoskeletal Pain Epidemiology in Japan (2017-2030)
  • Figure 16 : Musculoskeletal Pain Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)